The US Food and Drug Administration (FDA) this week granted an emergency use authorization (EUA) to Synapse Biomedical of Oberlin, Ohio, to permit the use of its TransAeris diaphragm pacing stimulator system to assist in weaning patients with coronavirus disease (COVID-19) off mechanical ventilation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,